Drug Profile
Research programme: protein A mimetics - Liminal BioSciences
Alternative Names: Mimetic A; PBI-0032; PBI-1308Latest Information Update: 14 Oct 2019
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Laboratorios Dermatologicos Darier; Liminal BioSciences
- Class Triazines
- Mechanism of Action Fc receptor antagonists; Immunomodulators; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Autoimmune disorders; Glomerulonephritis; Prostate cancer; Psoriasis
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 28 Jun 2018 No recent reports of development identified for preclinical development in Glomerulonephritis in Canada (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in Canada (PO)